Despite the fact that Sales of Acomplia Lag, Sanofi Still Has High Hopes
With sales of Acomplia (rimonabant) lagging in
the several dozen countries where it is on the market, Sanofi-Aventis
executives had little to say about their pioneering obesity treatment
in a report to analysts on Feb. . But that hardly means they have given
up on the CB-1 receptor antagonist.
the several dozen countries where it is on the market, Sanofi-Aventis
executives had little to say about their pioneering obesity treatment
in a report to analysts on Feb. . But that hardly means they have given
up on the CB-1 receptor antagonist.
Instead,
Sanofi unveiled plans to make at least three presentations at major
U.S. and European medical meetings during 2008 on the results of
clinical trials of Acomplia as a treatment for heart disease and
diabetes.
Sanofi unveiled plans to make at least three presentations at major
U.S. and European medical meetings during 2008 on the results of
clinical trials of Acomplia as a treatment for heart disease and
diabetes.
And as a strong indication
that the results Sanofi Aventis is seeing from the diabetes trials
continue to look really good, the French company reiterated that it
plans to seek for FDA approval of rimonabant (to be called Zimulti in
the United States), this time for treatment of diabetes, in 2009.
that the results Sanofi Aventis is seeing from the diabetes trials
continue to look really good, the French company reiterated that it
plans to seek for FDA approval of rimonabant (to be called Zimulti in
the United States), this time for treatment of diabetes, in 2009.
So
where do things stand on the hopes of millions of obese and
overweight people that rimonabant would become the next
blockbuster pill for treatment of obesity?
where do things stand on the hopes of millions of obese and
overweight people that rimonabant would become the next
blockbuster pill for treatment of obesity?
Well,
Sanofi reported that fourth quarter sales of Acomplia worldwide totaled
21 million Euros (approximately US $30.6 million) — unchanged from the
21 million Euros in sales that Sanofi reported for the third quarter of
2007.
Sanofi reported that fourth quarter sales of Acomplia worldwide totaled
21 million Euros (approximately US $30.6 million) — unchanged from the
21 million Euros in sales that Sanofi reported for the third quarter of
2007.
He said results of
the ARPEGGIO study, evaluating rimonabant in combination with insulin
for treatment of diabetes, will be presented to the American Diabetes
Association at its annual meeting in June 2008.
the ARPEGGIO study, evaluating rimonabant in combination with insulin
for treatment of diabetes, will be presented to the American Diabetes
Association at its annual meeting in June 2008.
Cluzel
also said Sanofi is awaiting further recommendations from the FDA on
the tracking during clinical trials of depressive side-effects
associated with rimonabant — the problem that led in mid-2007 to
Sanofi’s withdrawal of its application to have Zimulti approved for
sale as an obesity drug in the U.S.
also said Sanofi is awaiting further recommendations from the FDA on
the tracking during clinical trials of depressive side-effects
associated with rimonabant — the problem that led in mid-2007 to
Sanofi’s withdrawal of its application to have Zimulti approved for
sale as an obesity drug in the U.S.
“As
for side effects, we are in conformity with FDA recommendations
particularly when it comes to psychiatric effects, suicidal ideas are
very much in the limelight, and of course, this applies for the whole
class of CB1s as well as for antiepileptic pills and antidepressives as
a class,” Cluzel declared.
for side effects, we are in conformity with FDA recommendations
particularly when it comes to psychiatric effects, suicidal ideas are
very much in the limelight, and of course, this applies for the whole
class of CB1s as well as for antiepileptic pills and antidepressives as
a class,” Cluzel declared.
“So we are waiting to see what the FDA recommendations will be,” he also said.
So
Acomplia will be on the american market sooner or later as an weight
loss pill or as a pill that treats diabetes.Will hope that happens
really soon because millions of people need it!
Acomplia will be on the american market sooner or later as an weight
loss pill or as a pill that treats diabetes.Will hope that happens
really soon because millions of people need it!
No Comments »
No comments yet.
Leave a comment
If you want to leave a feedback to this post or to some other user´s comment, simply fill out the form below.